FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Kirkwood

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Dendritic Cells

Co-author Network

Publications

TOP 3
Diwakar Davar; Ahmad A Tarhini; John M Kirkwood
Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Antoni Ribas; Jacob Schachter; Michael Smylie; Uwe Trefzer; Brigitte Dreno; Claus Garbe; Helen Gogas; Jesus Gomez-Navarro; John B Haanen; Bo Huang; Richard Kefford; Kari L Kendra; John M Kirkwood; Gerald Linette; Paul Lorigan; Jacek Mackiewicz; Michele Maio; Maribel Marmol; Margaret A Marshall; Grant A McArthur; Paul D Nathan; Dmitri Pavlov; Cornelis J A Punt; Axel Hauschild
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
John M Kirkwood; Prapti Patel; Joan H Schiller; Joseph A Sparano; Ahmad A Tarhini; Al B Benson Iii; Maxwell T Vergo; Hussein Tawbi
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Kirkwood (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Diwakar Davar; Ahmad A Tarhini; John M Kirkwood
Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Clinics in dermatology 2013;31(3):237-50.
2013: Antoni Ribas; Jacob Schachter; Michael Smylie; Uwe Trefzer; Brigitte Dreno; Claus Garbe; Helen Gogas; Jesus Gomez-Navarro; John B Haanen; Bo Huang; Richard Kefford; Kari L Kendra; John M Kirkwood; Gerald Linette; Paul Lorigan; Jacek Mackiewicz; Michele Maio; Maribel Marmol; Margaret A Marshall; Grant A McArthur; Paul D Nathan; Dmitri Pavlov; Cornelis J A Punt; Axel Hauschild
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(5):616-22.
2013: John M Kirkwood; Prapti Patel; Joan H Schiller; Joseph A Sparano; Ahmad A Tarhini; Al B Benson Iii; Maxwell T Vergo; Hussein Tawbi
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.
Cancer treatment reviews 2013;39(1):27-43.
2013: Keith T Flaherty; Lawrence E Flaherty; Richard Kefford; Sandra J Lee; Philip Leming; Lynn M Schuchter; Fengmin Zhao; Michael B Atkins; John M Kirkwood
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):373-9.
2013: Anna Guastafierro; John M Kirkwood; Patrick S Moore; Yuan Chang; Huichen Feng; Mamie Thant; MASAHIRO SHUDA
Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice.
Journal of virological methods 2013;187(1):6-14.
2012: Ahmad A Tarhini; Yongli Shuai; Lisa H Butterfield; William E Gooding; Pawel Kalinski; John M Kirkwood
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(9):702-10.
2012: Georgina V Long; Anne-Marie Martin; Laurent Mortier; Igor Puzanov; Caroline Robert; Michael Streit; Suzanne Swann; Julie Switzky; Hussein Tawbi; Uwe Trefzer; Tabea Wilhelm; Lisa Zimmer; Alain Algazi; Paolo A Ascierto; Paul B Chapman; Michael A Davies; Vicki Goodman; Mary Guckert; Axel Hauschild; Richard F Kefford; John M Kirkwood; Dirk Schadendorf
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
The lancet oncology 2012;13(11):1087-95.
2012: Ahmad A Tarhini; John M Kirkwood
How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(31):3773-6.
2012: Ahmad A Tarhini; Helen Gogas; John M Kirkwood
IFN-α in the treatment of melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(8):3789-93.
2012: Hussein A Tawbi; John M Kirkwood
Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect.
Nature reviews. Clinical oncology 2012;9(9):496-7.
2012: John M Kirkwood; Ahmad A Tarhini; Hassane M Zarour; Lisa H Butterfield; Pawel Kalinski; Soldano Ferrone
Immunotherapy of cancer in 2012.
CA: a cancer journal for clinicians 2012;62(5):309-35.
2012: Carsten Schaefer; Carmen Visus; Andreas Albers; Lisa H Butterfield; Grace G Kim; John M Kirkwood; Sandra Lee; Theresa L Whiteside
Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696).
International journal of cancer. Journal international du cancer 2012;131(4):874-84.
2012: Ahmad A Tarhini; Yan Yin; William E Gooding; Siyang Leng; Yan Lin; Stergios J Moschos; Cindy Sander; John M Kirkwood
Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(4):359-66.
2012: Diwakar Davar; Ahmad A Tarhini; John M Kirkwood
Adjuvant therapy for melanoma.
Cancer journal (Sudbury, Mass.) 2012;18(2):192-202.
2012: Douglas M Potter; Cindy A Sander; Lisa H Butterfield; Sherrie J Divito; John M Kirkwood
Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients.
Journal of immunological methods 2012;376(1-2):108-12.
2012: Ahmad A Tarhini; Hussein Tawbi; John Cherian; William Gooding; Stergios J Moschos; Cindy Sander; Yongli Shuai; John M Kirkwood
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):322-8.
2012: Antoni Ribas; Vernon K Sondak; Mark R Middleton; Keith T Flaherty; Helen Gogas; Peter Hersey; John M Kirkwood
New challenges in endpoints for drug development in advanced melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):336-41.
2012: John M Kirkwood; James Larkin; Mark Middleton; Caroline Robert; Jeff Sosman; Victoria Zazulina; Lars Bastholt; Mireille Cantarini; Peter Hersey; Karin Kemsley; Reinhard Dummer
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):555-67.
2012: Jonhan Ho; Lin Hui-Min; John M Kirkwood; Yan Lin; Dorothea Becker; Michelle Barbi de Moura; Lyn M Duncan; Stephen Thorne; Bennett Van Houten; Garret Vincent; Stergios J Moschos
Importance of glycolysis and oxidative phosphorylation in advanced melanoma.
Molecular cancer 2012;11():76.
2012: Michelle Barbi de Moura; Nicholas W Bateman; Dorothea Becker; Thomas P Conrads; Stefan Duensing; Shelley L Fayewicz; Brian L Hood; John M Kirkwood; Cindy Sander; Joseph Suhan; Mai Sun; Bennett Van Houten; Garret Vincent; Yan Yin; Stergios J Moschos
Mitochondrial respiration--an important therapeutic target in melanoma.
PloS one 2012;7(8):e40690.
2011: Ahmad A Tarhini; Kim A Margolin; Christopher Ruel; Janice Shipe-Spotloe; Alice Chen; Scott Christensen; Paul Frankel; David R Gandara; John M Kirkwood
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(20):6574-81.
2011: John M Kirkwood; Robert R McWilliams; Douglas Reintgen; Annamaria Zimmermann; Michael P Brown; Philip R Clingan; Dinesh P de Alwis; Rene Gonzalez; Robert L Ilaria; Michael J Millward
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Cancer 2011;117(20):4732-9.
2011: John M Kirkwood
Melanoma response and resistance - taking it to the tumor bank.
Pigment cell & melanoma research 2011;24(5):978-9.
2011: Hussein Tawbi; L Villaruz; F Viverette; Stergios J Moschos; R Radkowski; Janice Shipe-Spotloe; M Sulecki; Ahmad A Tarhini; John M Kirkwood
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
British journal of cancer 2011;105(6):773-7.
2011: Ahmad A Tarhini; Shalu Pahuja; John M Kirkwood
Neoadjuvant therapy for high-risk bulky regional melanoma.
Journal of surgical oncology 2011;104(4):386-90.
2011: Pawel Kalinski; John M Kirkwood; Hideho Okada; Herbert J Zeh; Lisa H Butterfield; Howard D Edington; David L Bartlett
Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
Immunologic research 2011;50(2-3):235-47.
2011: Michal T Krauze; Ahmad Tarhini; Helen Gogas; John M Kirkwood
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Seminars in immunopathology 2011;33(4):385-91.
2011: Xi Zhao; Anamika Bose; Hideo Komita; Jennifer L Taylor; Mayumi Kawabe; Nina Chi; Laima Spokas; Devin B Lowe; Christina Goldbach; Sean Alber; Simon C Watkins; Lisa H Butterfield; Pawel Kalinski; John M Kirkwood; Walter J Storkus
Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(4):805-14.
2011: Lisa H Butterfield; Douglas M Potter; John M Kirkwood
Multiplex serum biomarker assessments: technical and biostatistical issues.
Journal of translational medicine 2011;9():173.
2011: Pavol Kudela; Zhaojun Sun; Julien Fourcade; Bratislav Janjic; John M Kirkwood; Bernard Maillere; Hassane M Zarour
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(1):312-22.
2010: Ahmad A Tarhini; John M Kirkwood
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.
Oncology (Williston Park, N.Y.) 2010;24(14):1302, 1304.
2010: Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
The Journal of experimental medicine 2010;207(10):2175-86.
2010: Julien Fourcade; Zhaojun Sun; Pavol Kudela; Bratislav Janjic; John M Kirkwood; Talal El-Hafnawy; Hassane M Zarour
Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(12):6709-18.
2010: Stergios J Moschos; Cindy A Sander; Wenjun Wang; Shelley L Reppert; Laura M Drogowski; Drazen M Jukic; Uma N M Rao; Charalambos Athanassiou; Manuela Buzoianu; Maja Mandic; Laura K Richman; LuAnn McKinney; Joel Leininger; David A Tice; Luz D Hammershaimb; John M Kirkwood
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(3):316-25.
2010: Payal B Watchmaker; Erik Berk; Ravikumar Muthuswamy; Robbie B Mailliard; Julie A Urban; John M Kirkwood; Pawel Kalinski
Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(2):591-7.
2010: Drazen M Jukic; Uma N M Rao; Lori Kelly; Jihad S Skaf; Laura M Drogowski; John M Kirkwood; Monica C Panelli
Microrna profiling analysis of differences between the melanoma of young adults and older adults.
Journal of translational medicine 2010;8():27.
2009: Ahmad A Tarhini; John M Kirkwood
Clinical and immunologic basis of interferon therapy in melanoma.
Annals of the New York Academy of Sciences 2009;1182():47-57.
2009: John M Kirkwood; Drazen M Jukic; Bruce J Averbook; Leonard S Sender
Melanoma in pediatric, adolescent, and young adult patients.
Seminars in oncology 2009;36(5):419-31.
2009: MASAHIRO SHUDA; Reety Arora; Hyun Jin Kwun; Huichen Feng; Ronit Sarid; María-Teresa Fernández-Figueras; Yanis Tolstov; Ole V Gjoerup; Mahesh M Mansukhani; Steven H Swerdlow; Preet M Chaudhary; John M Kirkwood; Michael A Nalesnik; Jeffrey A Kant; Lawrence M Weiss; Patrick S Moore; Yuan Chang
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors.
International journal of cancer. Journal international du cancer 2009;125(6):1243-9.
2009: Ahmad A Tarhini; John M Kirkwood; Arthur M Krieg
Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.
Expert opinion on drug discovery 2009;4(5):587-603.
2009: Julien Fourcade; Pavol Kudela; Zhaojun Sun; Hongmei Shen; Stephanie R Land; Diana Lenzner; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; Soldano Ferrone; John M Kirkwood; Hassane M Zarour
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(9):5240-9.
2009: John M Kirkwood; Alexander Eggermont
Highlights from the perspectives in melanoma XII conference.
Pigment cell & melanoma research 2009;22(2):156-65.
2009: Helen Gogas; John M Kirkwood
Predictors of response to interferon therapy.
Current opinion in oncology 2009;21(2):138-43.
2009: John M Kirkwood; Sandra Lee; Stergios J Moschos; Mark R Albertini; John C Michalak; Cindy Sander; Theresa Whiteside; Lisa H Butterfield; Louis Weiner
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1443-51.
2009: Ahmad A Tarhini; Michael Millward; Paul Mainwaring; Richard Kefford; Ted Logan; Anna Pavlick; Steven J Kathman; Kevin H Laubscher; Mohammed M Dar; John M Kirkwood
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
Cancer 2009;115(4):859-68.
2009: John M Kirkwood; Hussein Tawbi; Ahmad A Tarhini; Stergios J Moschos
Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?
Nature clinical practice. Oncology 2009;6(2):70-1.
2009: Ahmad A Tarhini; Joseph Stuckert; Sandra Lee; Cindy Sander; John M Kirkwood
Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):38-44.
2008: Julien Fourcade; Pavol Kudela; Pedro A Andrade Filho; Bratislav Janjic; Stephanie R Land; Cindy Sander; Arthur Krieg; Albert D Donnenberg; Hongmei Shen; John M Kirkwood; Hassane M Zarour
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(8):781-91.
2008: Ahmad A Tarhini; John M Kirkwood
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
Expert opinion on biological therapy 2008;8(10):1583-93.
2008: Ahmad A Tarhini; John M Kirkwood; William Gooding; Stergios Moschos; Sanjiv S Agarwala
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Cancer 2008;113(7):1632-40.
2008: Wenjun Wang; Howard D Edington; Drazen M Jukic; Uma N M Rao; Stephanie R Land; John M Kirkwood
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Cancer immunology, immunotherapy : CII 2008;57(9):1315-21.
2008: Wenjun Wang; Howard D Edington; Uma N M Rao; Drazen M Jukic; Hong Wang; Janice M Shipe-Spotloe; John M Kirkwood
STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
The Journal of investigative dermatology 2008;128(8):1997-2002.
2008: John M Kirkwood; Ahmad A Tarhini; Monica C Panelli; Stergios J Moschos; Hassane M Zarour; Lisa H Butterfield; Helen J Gogas
Next generation of immunotherapy for melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3445-55.
2008: Stergios J Moschos; Preet M Chaudhary; John M Kirkwood
Resolving "kinks" of chemotherapy in melanoma.
Journal of the National Cancer Institute 2008;100(12):833-5.
2008: Michael J Robertson; John M Kirkwood; Theodore F Logan; Kevin M Koch; Steven Kathman; Lyndon Kirby; William N Bell; Linda M Thurmond; Jill Weisenbach; Mohammed M Dar
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3462-9.
2008: Stergios J Moschos; Maja Mandic; John M Kirkwood; Walter J Storkus; Michael T Lotze
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
Clinical immunology (Orlando, Fla.) 2008;127(2):123-9.
2008: Laura Strauss; Christoph Bergmann; Miroslaw J Szczepanski; Stephan Lang; John M Kirkwood; Theresa L Whiteside
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(5):2967-80.
2008: Ahmad A Tarhini; John M Kirkwood; Hussein Tawbi; William Gooding; Mohammed F Islam; Sanjiv S Agarwala
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.
Cancer 2008;112(5):1131-8.
2008: John M Kirkwood; Ahmad A Tarhini; Stergios J Moschos; Monica C Panelli
Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
Nature clinical practice. Oncology 2008;5(1):2-3.
2007: Hussein A Tawbi; John M Kirkwood
Management of metastatic melanoma.
Seminars in oncology 2007;34(6):532-45.
2007: Pavol Kudela; Bratislav Janjic; Julien Fourcade; Florence A Castelli; Pedro Andrade; John M Kirkwood; Talal El-Hefnawy; Massimo Amicosante; Bernard Maillere; Hassane M Zarour
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(11):7932-40.
2007: Lazar Vujanovic; Maja Mandic; Walter C Olson; John M Kirkwood; Walter J Storkus
A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(22 Pt 1):6796-806.
2007: Ahmad A Tarhini; John M Kirkwood
Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
Current opinion in molecular therapeutics 2007;9(5):505-14.
2007: Stergios J Moschos; John M Kirkwood
Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.
Cytokine & growth factor reviews 2007;18(5-6):451-8.
2007: Ahmad A Tarhini; John M Kirkwood; William Gooding; Chao Cai; Sanjiv S Agarwala
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3802-7.
2007: Stergios J Moschos; Laura M Drogowski; Shelley L Reppert; John M Kirkwood
Integrins and cancer.
Oncology (Williston Park, N.Y.) 2007;21(9 Suppl 3):13-20.
2007: Stergios J Moschos; Amanda Pfaff Smith; Maja Mandic; C Athanassiou; K Watson-Hurst; Drazen M Jukic; Howard D Edington; John M Kirkwood; D Becker
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.
Oncogene 2007;26(29):4216-25.
2007: Ahmad A Tarhini; John M Kirkwood
Oblimersen in the treatment of metastatic melanoma.
Future oncology (London, England) 2007;3(3):263-71.
2007: Stergios J Moschos; Christine Odoux; Stephanie R Land; Sanjiv Agarwala; David M Friedland; Kirk M Volker; Carolyn Sidor; Michael Wong; John M Kirkwood
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
Melanoma research 2007;17(3):193-200.
2007: Zoya R Yurkovetsky; John M Kirkwood; Howard D Edington; Adele M Marrangoni; Lyudmila Velikokhatnaya; Matthew T Winans; Elieser Gorelik; Anna Lokshin
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2422-8.
2007: Wenjun Wang; Howard D Edington; Uma N M Rao; Drazen M Jukic; Stephanie R Land; Soldano Ferrone; John M Kirkwood
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(5):1523-31.
2007: Amy Wesa; Pawel Kalinski; John M Kirkwood; Tomohide Tatsumi; Walter J Storkus
Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(1):75-82.
2006: T Clark Gamblin; Howard D Edington; John M Kirkwood; Uma N M Rao
Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features.
Annals of surgical oncology 2006;13(12):1664-70.
2006: Bratislav Janjic; Pedro Andrade; Xiao-Fei Wang; Julien Fourcade; Christine Almunia; Pavol Kudela; Adam Brufsky; Samuel Jacobs; David M Friedland; Ronald G Stoller; Daniel Gillet; Ronald Herberman; John M Kirkwood; Bernard Maillere; Hassane M Zarour
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(4):2717-27.
2006: Demetrius M Kokkinakis; Anthony Brickner; John M Kirkwood; Xiaoyan Liu; Jason E Goldwasser; Anastasiya Kastrama; Cindy Sander; Dora Bocangel; Sunil Chada
Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress.
Molecular cancer research : MCR 2006;4(8):575-89.
2006: Lazar Vujanovic; Elena Ranieri; Andrea Gambotto; Walter C Olson; John M Kirkwood; Walter J Storkus
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
Cancer gene therapy 2006;13(8):798-805.
2006: Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N M Rao; Drazen M Jukic; Janice Shipe-Spotloe; John M Kirkwood
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3164-71.
2006: Ahmad A Tarhini; Janice Shipe-Spotloe; Melissa DeMark; Sanjiv S Agarwala; John M Kirkwood
Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".
The oncologist 2006;11(5):538-9; author reply 539-40.
2006: John M Kirkwood; Stergios J Moschos; Wenjun Wang
Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 2):2331s-2336s.
2006: Anna Wankowicz-Kalinska; Robbie B Mailliard; Kathleen Olson; Fiona Graham; Howard D Edington; John M Kirkwood; Stephanie Martinek; Pranab K Das; Walter J Storkus
Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
Melanoma research 2006;16(2):165-74.
2005: Douglas Kondziolka; Juan J Martin; John C Flickinger; David M Friedland; Adam Brufsky; Joseph Baar; Sanjiv Agarwala; John M Kirkwood; L Dade Lunsford
Long-term survivors after gamma knife radiosurgery for brain metastases.
Cancer 2005;104(12):2784-91.
2005: Robbie B Mailliard; Sean Alber; Hongmei Shen; simon simon watkins; John M Kirkwood; Ronald Herberman; Pawel Kalinski
IL-18-induced CD83+CCR7+ NK helper cells.
The Journal of experimental medicine 2005;202(7):941-53.
2005: Pawel Kalinski; Robbie B Mailliard; Adam Giermasz; Herbert J Zeh; Per H Basse; David L Bartlett; John M Kirkwood; Michael T Lotze; Ronald Herberman
Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Expert opinion on biological therapy 2005;5(10):1303-15.
2005: Ahmad A Tarhini; Stephanie Land; Akshay Gupta; John M Kirkwood
Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?
Nature clinical practice. Oncology 2005;2(5):240-1.
2005: Maja Mandic; Florence A Castelli; Bratislav Janjic; Christine Almunia; Pedro Andrade; Daniel Gillet; Vladimir Brusic; John M Kirkwood; Bernard Maillere; Hassane M Zarour
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(3):1751-9.
2005: Pawel Kalinski; Adam Giermasz; Yutaro Nakamura; Per H Basse; Walter J Storkus; John M Kirkwood; Robbie B Mailliard
Helper role of NK cells during the induction of anticancer responses by dendritic cells.
Molecular immunology 2005;42(4):535-9.
2005: Peter C Gerszten; Steven A. Burton; Annette Quinn; Sanjiv S Agarwala; John M Kirkwood
Radiosurgery for the treatment of spinal melanoma metastases.
Stereotactic and functional neurosurgery 2005;83(5-6):213-21.
2005: Stergios J Moschos; Sai Varanasi; John M Kirkwood
Interferons in the treatment of solid tumors.
Cancer treatment and research 2005;126():207-41.
2005: Stergios J Moschos; Panagiotis A Konstantinopoulos; John M Kirkwood
Melanoma.
Cancer chemotherapy and biological response modifiers 2005;22():563-90.
2005: David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffrey R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):133-41.
2004: Robbie B Mailliard; Anna Wankowicz-Kalinska; Quan Cai; Amy Wesa; Catharien M Hilkens; Martien L Kapsenberg; John M Kirkwood; Walter J Storkus; Pawel Kalinski
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.
Cancer research 2004;64(17):5934-7.
2004: Sanjiv S Agarwala; Rajiv Panikkar; John M Kirkwood
Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver.
Melanoma research 2004;14(3):217-22.
2004: Sanjiv S Agarwala; John M Kirkwood; Martin Gore; Brigitte Dreno; Nicholas Thatcher; Beate Czarnetski; Michael Atkins; Antonio C Buzaid; Dimosthenis Skarlos; Elaine M Rankin
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2101-7.
2004: Sanjiv S Agarwala; Donna Neuberg; Yuhyun Park; John M Kirkwood
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Cancer 2004;100(8):1692-8.
2004: John M Kirkwood; Judith Manola; Joseph G Ibrahim; vernon sondak; Marc S Ernstoff; Uma Rao
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1670-7.
2004: Talal El-Hefnawy; Siva Raja; Lori Kelly; William L Bigbee; John M Kirkwood; James D Luketich; Tony E Godfrey
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics.
Clinical chemistry 2004;50(3):564-73.
2004: Shannon L McDonald; Howard D Edington; John M Kirkwood; Dorothea Becker
Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes.
Cancer biology & therapy 2004;3(1):110-20.
2004: Stergios J Moschos; John M Kirkwood; Panagiotis A Konstantinopoulos
Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):11-4.
2003: Maja Mandic; Christine Almunia; Stephanie Vicel; Daniel Gillet; Bratislav Janjic; Kara Coval; Bernard Maillere; John M Kirkwood; Hassane M Zarour
The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Cancer research 2003;63(19):6506-15.
2003: Hassane M Zarour; John M Kirkwood
Melanoma vaccines: early progress and future promises.
Seminars in cutaneous medicine and surgery 2003;22(1):68-75.
2003: Larisa Geskin; C Romen Brown; John M Kirkwood
Adjuvant therapy of melanoma.
Seminars in cutaneous medicine and surgery 2003;22(1):55-67.
2003: Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; James H Finke; Ronald M Bukowski; Vladimir Brusic; John Sidney; Alessandro Sette; Theodore F Logan; Yvette L Kasamon; Craig L Slingluff; John M Kirkwood; Walter J Storkus
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):947-54.
2003: John M Kirkwood; Ahmad A Tarhini
Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
Forum (Genoa, Italy) 2003;13(2):127-40; quiz 187-8.
2003: Amanda Pfaff Smith; John M Kirkwood; Howard D Edington; Drazen M Jukic; Daniel L Farkas; Dorothea Becker
Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment.
Molecular imaging 2003;2(1):65-73.
2003: Sanjiv S Agarwala; John M Kirkwood
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Cancer 2003;97(1):121-7.
2002: John M Kirkwood; Joseph G Ibrahim; vernon sondak; Marc S Ernstoff; Lawrence E Flaherty; Frank J Haluska
Use and abuse of statistics in evidence-based medicine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4122-3; author reply 4123-4.
2002: Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; James H Finke; Ronald M Bukowski; Jan Muller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
The Journal of experimental medicine 2002;196(5):619-28.
2002: Sanjiv S Agarwala; John M Kirkwood
Update on adjuvant interferon therapy for high-risk melanoma.
Oncology (Williston Park, N.Y.) 2002;16(9):1177-87; discussion 1190-2, 1197.
2002: John M Kirkwood; Thomas Richards; Hassane M Zarour; Jeffrey A Sosman; Marc S Ernstoff; Theresa L Whiteside; Joseph G Ibrahim; Ronald Blum; Samuel Wieand; Ruth Mascari
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Cancer 2002;95(5):1101-12.
2002: John M Kirkwood; Catherine Bender; Sanjiv Agarwala; Ahmad A Tarhini; Janice Shipe-Spotloe; Barbara Smelko; Sandra Donnelly; Lori Stover
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3703-18.
2002: Mohammed Islam; Reginald F Frye; Thomas J Richards; Ibraham Sbeitan; Sandra S Donnelly; Paul Glue; Sanjiv S Agarwala; John M Kirkwood
Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2480-7.
2002: Uma N M Rao; Joseph G Ibrahim; Lawrence E Flaherty; J Richards; John M Kirkwood
Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2053-7.
2002: Hassane M Zarour; Bernard Maillere; Vladimir Brusic; Kara Coval; Eileen Williams; Sandra Pouvelle-Moratille; Florence A Castelli; Stephanie Land; Jaafar Bennouna; Theodore Logan; John M Kirkwood
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Cancer research 2002;62(1):213-8.
2002: Sanjiv S Agarwala; John Glaspy; Steven J O'Day; Malcolm Mitchell; John C Gutheil; Eric Whitman; Rene Gonzalez; Evan M Hersh; Lynn Feun; Robert Belt; Frank Meyskens; Kristoffer Hellstrand; Diana Wood; John M Kirkwood; Kurt Gehlsen; Peter Naredi
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):125-33.
2001: Lisa S Kierstead; Elena Ranieri; Walter Olson; Vladimir Brusic; John Sidney; Alessandro Sette; Yvette L Kasamon; Craig L Slingluff; John M Kirkwood; Walter J Storkus
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.
British journal of cancer 2001;85(11):1738-45.
2001: John M Kirkwood; Joseph G Ibrahim; Jeffrey A Sosman; vernon sondak; Sanjiv S Agarwala; Marc S Ernstoff; Uma Rao
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2370-80.
2001: Clemens Esche; Galina V Shurin; John M Kirkwood; G Q Wang; Hannah Rabinowich; Georgi Pirtskhalaishvili; Michael R Shurin
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3 Suppl):974s-979s.
2001: John M Kirkwood; Joseph G Ibrahim; D H Lawson; M B Atkins; Sanjiv S Agarwala; K Collins; Ruth Mascari; Donna M Morrissey; Paul B Chapman
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1430-6.
2000: Howard D Edington; S Agarwala; John M Kirkwood
Biologic therapy.
Clinics in plastic surgery 2000;27(4):643-65.
2000: Hassane M Zarour; Walter J Storkus; Vladimir Brusic; E Williams; John M Kirkwood
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Cancer research 2000;60(17):4946-52.
2000: Catherine M Bender; Joyce M Yasko; John M Kirkwood; C Ryan; Jacqueline Dunbar-Jacob; Thomas G Zullo
Cognitive function and quality of life in interferon therapy for melanoma.
Clinical nursing research 2000;9(3):352-63.
2000: Sanjiv S Agarwala; John M Kirkwood
Update on the role of adjuvant interferon for high risk melanoma.
Forum (Genoa, Italy) 2000;10(3):230-9.
2000: Michael R Shurin; John M Kirkwood; Clemens Esche
Cytokine-based therapy for melanoma: pre-clinical studies.
Forum (Genoa, Italy) 2000;10(3):204-26.
2000: John M Kirkwood; Ruth Mascari; Howard D Edington; M S Rabkin; Roger S Day; Theresa L Whiteside; Daniel Vlock; Janice Shipe-Spotloe
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
Cancer 2000;88(12):2693-702.
2000: John M Kirkwood; Joseph G Ibrahim; vernon sondak; J Richards; Lawrence E Flaherty; Marc S Ernstoff; T J Smith; Uma Rao; M Steele; Ronald Blum
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2444-58.
2000: Elena Ranieri; Lisa S Kierstead; Hassane M Zarour; John M Kirkwood; Michael T Lotze; Theresa L Whiteside; Walter J Storkus
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading.
Immunological investigations 2000;29(2):121-5.
2000: Michael T Lotze; Michael R Shurin; Clemens Esche; Hideaki Tahara; Walter J Storkus; John M Kirkwood; Theresa L Whiteside; Elaine Elder; H Okada; Paul D Robbins
Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.
The cancer journal from Scientific American 2000;6 Suppl 1():S61-6.
2000: Hassane M Zarour; John M Kirkwood; Lisa S Kierstead; W Herr; Vladimir Brusic; Craig L Slingluff; John Sidney; Alessandro Sette; Walter J Storkus
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(1):400-5.
2000: Sanjiv S Agarwala; John M Kirkwood
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
The oncologist 2000;5(2):144-51.
1999: P Yang; Daniel L Farkas; John M Kirkwood; John L Abernethy; Howard D Edington; Dorothea Becker
Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma.
Molecular medicine (Cambridge, Mass.) 1999;5(12):785-94.
1999: Sanjiv S Agarwala; W Ferri; William Gooding; John M Kirkwood
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Cancer 1999;85(9):1979-84.
1999: John M Kirkwood; Daniel L Farkas; Arup Chakraborty; Kevin F Dyer; David Tweardy; John L Abernethy; Howard D Edington; S S Donnelly; Dorothea Becker
Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.
Molecular medicine (Cambridge, Mass.) 1999;5(1):11-20.
1998: Theodore F Logan; B Banner; Uma Rao; Marc S Ernstoff; N Wolmark; Theresa L Whiteside; LM Miketic; John M Kirkwood
Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy.
Clinical and experimental immunology 1998;114(3):347-54.
1998: John M Kirkwood
Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.
European journal of cancer (Oxford, England : 1990) 1998;34 Suppl 3():S12-7.
1998: John M Kirkwood
Adjuvant IFN alpha2 therapy of melanoma.
Lancet 1998;351(9120):1901-3.
1998: Sanjiv S Agarwala; John M Kirkwood
Adjuvant therapy of melanoma.
Seminars in surgical oncology 1998;14(4):302-10.
1997: Robert P Edwards; William Gooding; Barry C Lembersky; K Colonello; R Hammond; C Paradise; C D Kowal; Alan J Kunschner; Marie Baldisseri; John M Kirkwood; Ronald Herberman
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(11):3399-407.
1997: Theodore F Logan; William Gooding; Theresa L Whiteside; Marc S Ernstoff; Sandra S Kaplan; LM Miketic; Daniel Vlock; C Tompkins; D L Wood; P I Nadler; John M Kirkwood
Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(5):387-98.
1997: John M Kirkwood; J Bryant; J H Schiller; M M Oken; Ernest C Borden; Theresa L Whiteside
Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(2):146-57.
1997: John M Kirkwood; G D Resnick; B F Cole
Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
Seminars in oncology 1997;24(1 Suppl 4):S16-23.
1996: H el Kassas; John M Kirkwood
Adjuvant application of interferons.
Seminars in oncology 1996;23(6):737-43.
1996: Yihan Wang; U Rao; R Mascari; T J Richards; A J Panson; Howard D Edington; J M Shipe-Spotloe; S S Donnelly; John M Kirkwood; Dorothea Becker
Molecular analysis of melanoma precursor lesions.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(12):1733-40.
1996: D R Vlock; J Andersen; L A Kalish; Jonas T Johnson; John M Kirkwood; Theresa L Whiteside; Ronald Herberman; G S Adams; M M Oken; R E Haselow
Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(6):433-42.
1996: Hannah Rabinowich; M Banks; Torsten E Reichert; Theodore F Logan; John M Kirkwood; Theresa L Whiteside
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1263-74.
1996: David C Smith; S L Gerson; L Liu; S Donnelly; R Day; Donald L Trump; John M Kirkwood
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1129-34.
1996: S S Agarwala; John M Kirkwood
Interferons in melanoma.
Current opinion in oncology 1996;8(2):167-74.
1996: Markus J Maeurer; Walter J Storkus; John M Kirkwood; Michael T Lotze
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines.
Melanoma research 1996;6(1):11-24.
1996: John M Kirkwood; M H Strawderman; Marc S Ernstoff; T J Smith; Ernest C Borden; Ronald Blum
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):7-17.
1996: Theodore F Logan; William Gooding; John M Kirkwood; R K Shadduck
Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients.
Experimental hematology 1996;24(1):49-53.
1995: S S Agarwala; John M Kirkwood
Potential uses of interferon alpha 2 as adjuvant therapy in cancer.
Annals of surgical oncology 1995;2(4):365-71.
1994: John M Kirkwood
Systemic therapy of melanoma.
Current opinion in oncology 1994;6(2):204-11.
1994: D R Vlock; Carl H Snyderman; Jonas T Johnson; E N Myers; David E Eibling; J S Rubin; John M Kirkwood; J P Dutcher; G L Adams
Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(2):134-9.
1993: Theodore F Logan; W Shannon; J Bryant; P Kane; N Wolmark; M Posner; John M Kirkwood; Marc S Ernstoff; J W Futrell; L D Straw
Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute.
Melanoma research 1993;3(6):451-5.
1993: E Weidmann; Theodore F Logan; S Yasumura; John M Kirkwood; Massimo Trucco; Theresa L Whiteside
Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Cancer research 1993;53(20):4745-9.
1993: K Selvaggi; E A Saria; R Schwartz; D R Vlock; S Ackerman; N Wedel; John M Kirkwood; H Jones; Marc S Ernstoff
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):201-7.
1993: Linda Titus-Ernstoff; R L Barnhill; P H Duray; Marc S Ernstoff; John M Kirkwood
Dysplastic nevi in relation to superficial spreading melanoma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1993;2(2):99-101.
1992: N M Yeilding; C Gerstner; John M Kirkwood
Analysis of two human monoclonal antibodies against melanoma.
International journal of cancer. Journal international du cancer 1992;52(6):967-73.
1992: Theodore F Logan; Mohamed A Virji; William Gooding; F A Bontempo; Marc S Ernstoff; John M Kirkwood
Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor.
Journal of the National Cancer Institute 1992;84(23):1802-10.
1992: P H Duray; R DerSimonian; R Barnhill; K Stenn; Marc S Ernstoff; J Fine; John M Kirkwood
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions.
Journal of the American Academy of Dermatology 1992;27(5 Pt 1):741-9.
1992: John M Kirkwood
Preclinical studies, experimental therapeutics, and clinical management of advanced melanoma.
Current opinion in oncology 1992;4(2):368-79.
1992: L M Jost; John M Kirkwood; Theresa L Whiteside
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells.
Journal of immunological methods 1992;147(2):153-65.
1992: Marc S Ernstoff; William Gooding; S Nair; R R Bahnson; L M Miketic; B Banner; R Day; Theresa L Whiteside; Linda Titus-Ernstoff; John M Kirkwood
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Cancer research 1992;52(4):851-6.
1992: S Nair; Marc S Ernstoff; R R Bahnson; S Arthur; J Johnston; M A Downs; J Neuhart; John M Kirkwood
Interferon-induced reversible acute renal failure with nephrotic syndrome.
Urology 1992;39(2):169-72.
1992: R L Barnhill; G C Roush; Marc S Ernstoff; John M Kirkwood
Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V.
Journal of the American Academy of Dermatology 1992;26(2 Pt 1):185-90.
1992: R L Barnhill; G C Roush; Linda Titus-Ernstoff; Marc S Ernstoff; P H Duray; John M Kirkwood
Comparison of nonfamilial and familial melanoma.
Dermatology (Basel, Switzerland) 1992;184(1):2-7.
1991: John M Kirkwood
Studies of interferons in the therapy of melanoma.
Seminars in oncology 1991;18(5 Suppl 7):83-90.
1991: A D Roth; F J Hornicek; C G Gerstner; John M Kirkwood
Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma.
Clinical and experimental immunology 1991;86(1):163-72.
1991: G C Roush; R L Barnhill; Marc S Ernstoff; John M Kirkwood
Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI.
British journal of cancer 1991;64(2):373-6.
1991: Linda Titus-Ernstoff; Marc S Ernstoff; P H Duray; R L Barnhill; R Holubkov; John M Kirkwood
A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma.
Epidemiology (Cambridge, Mass.) 1991;2(3):210-4.
1991: Theodore F Logan; S S Kaplan; J L Bryant; Marc S Ernstoff; J R Krause; John M Kirkwood
Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(2):84-95.
1990: S M Luger; John M Kirkwood; Marc S Ernstoff; D R Vlock
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma.
Journal of the National Cancer Institute 1990;82(24):1934-7.
1990: John M Kirkwood; Marc S Ernstoff
Role of interferons in the therapy of melanoma.
The Journal of investigative dermatology 1990;95(6 Suppl):180S-184S.
1990: Marc S Ernstoff; S Nair; R R Bahnson; L M Miketic; B Banner; William Gooding; R Day; Theresa L Whiteside; T Hakala; John M Kirkwood
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1637-49.
1990: John M Kirkwood; M S Ernstoff; A Giuliano; Richard Gams; William A Robinson; J Costanzi; P Pouillart; J Speyer; M Grimm; R Spiegel
Interferon alpha-2a and dacarbazine in melanoma.
Journal of the National Cancer Institute 1990;82(12):1062-3.
1990: John M Kirkwood; J E Robinson
Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes.
Cancer immunology, immunotherapy : CII 1990;32(4):228-34.
1989: Linda Titus-Ernstoff; Marc S Ernstoff; John M Kirkwood; R L Barnhill; J Fine; P H Duray
Usefulness of frequent skin examination for the early detection of second primary cutaneous melanoma.
Cancer detection and prevention 1989;13(5-6):317-21.
1988: D R Vlock; D Scalise; N Meglin; John M Kirkwood; Byron Ballou
Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody.
The Journal of clinical investigation 1988;81(6):1746-51.
1988: G C Roush; J J Nordlund; B Forget; Stephen B Gruber; John M Kirkwood
Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma.
Preventive medicine 1988;17(3):273-9.
1988: Linda Titus-Ernstoff; P H Duray; Marc S Ernstoff; R L Barnhill; P L Horn; John M Kirkwood
Dysplastic nevi in association with multiple primary melanoma.
Cancer research 1988;48(4):1016-8.